Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Jun 11,2020
Introduction of common tumor model experimental animals
BALB/c mice BALB/c mice Features and uses: ◇ Its incidence is low, but it is sensitive to carcinogens. The incidence of breast tumors is about 10﹪~20﹪. ◇ There are a certain number of ovarian, adrenal and lung tumors, which are extremely sensitive to radiation. You are susceptible to chronic pneumonia.  ◇Most individuals develop immunoglobulin syndromeRead more
More
Introduction of common tumor model experimental animals
May 26,2020
Congratulations on the Successful Listing of Kintor Pharma
On May 22, 2020, Kintor Pharmaceutical Limited (stock code: 9939. HK) was officially listed on the Hong Kong Stock Exchange. We medicilon extend the congratulations and best wishes. Medicilon has joined hands with in multiple pharmaceutical development projects in recent years, including external preclinical pharmacokinetic studies and safety evaluation of the androgen receptor antagonist FrestatinRead more
More
Congratulations on the Successful Listing of Kintor Pharma
May 12,2020
Solve the four major problems and get the non-clinical research of CAR-T cells
On August 31, 2017, the US FDA approved the first gene therapy method for CAR-T cell therapy. The drug targets the antigen CD19, which is an antigen protein expressed on the surface of a variety of blood tumor cells, including B-cell lymphoma and leukemia cells, and is used for the treatment of relapsed or refractoryRead more
More
Solve the four major problems and get the non-clinical research of CAR-T cells
Apr 30,2020
The new anti-tumor weapon PDX model helps the development of new immune cancer drugs
On April 22, 2020, Dr. Chunlin Chen, founder and CEO of Medicilon, delivered a special lecture entitled "Application of Translational Medicine (PDX Model) in the Research and Development of New Immune Cancer Drugs” Run Run Shaw Hospital affiliated to Medical College of Zhejiang University . The medical staff and medical students of the company shared.
More
The new anti-tumor weapon PDX model helps the development of new immune cancer drugs
Apr 25,2020
Medicilon's Pharmacology Research
Medicilon's Technology Department aims to meet customers' one-stop service needs for API R&D, utilize rich medicinal chemistry experience to efficiently promote customers' drug R&D projects, promote new drug processes into new drug clinical research earlier, and effectively help customers Control the cost of new drug development. The process department currently has a total area ofRead more
More
Apr 07,2020
How to establish an accurate pharmacology animal evaluation model for popular diseases?
Malignant tumors, Alzheimer's disease, diabetes, rheumatoid arthritis… These intractable diseases that threaten human health have long plagued us, bringing pain and suffering to unfortunate patients, and also bringing frontline researchers Pressure and challenge. It is the peak that many scientific research institutions intend to leap, and it is also a hot potato that the marketRead more
More
How to establish an accurate pharmacology animal evaluation model for popular diseases?
Apr 04,2020
Nation Mourned Covid-19 Victims in China at April 4th
A national mourning period was held on Saturday, this year's Tomb Sweeping Day, to commemorate those who succumbed to COVID-19. To express profound condolences to martyrs who sacrificed their lives in fighting the novel coronavirus
More
Nation Mourned Covid-19 Victims in China at April 4th
Mar 30,2020
Overview of “medicine” news in a week [03.23-03.27]
Keep up with the forefront of new drugs, focus on R&D and innovationThis Week's news: • Eli Lilly's "Unlimited Canciner Type” RET inhibitor was approved by the FDA; • Enhua's subsidiary, Haoxinqing Medical, completed 125 million yuan in financing; • Alexion Pharmaceuticals announced the acquisition of Portola Pharmaceuticals at a high premium of US$1.44 billion.Read more
More
Overview of “medicine” news in a week [03.23-03.27]
Mar 25,2020
Medicilon Preclinical Research-Early Pharmacokinetics (Discovery DMPK) Team
Medicilon online lesson will start soon! [Cloud Archives] series will give you a detailed introduction to the lecturer's research fields and related information. Today, let us approach Dr. Ma Fei and the early pharmacokinetic team of Medicilon! Strictly check early and provide high-quality data The research and development of innovative drugs is a long-term processRead more
More
Mar 18,2020
Medicilon Preclinical Research-Pharmacodynamics Department
Medicilon online lesson will start soon! [Cloud File] series will introduce the lecturer's research field and related information in detail. Today, let us approach Dr. Dong Wenxin and Medicilon Pharmacodynamics Department! Professionals make professional things Medicilon's Pharmacodynamics Department is a high-quality professional team with deep professional theoretical knowledge and years of experimental experience. The teamRead more
More
Medicilon Preclinical Research-Pharmacodynamics Department
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->